Agilent Technologies, Inc.
A- Exchange
- NYSE
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001090872
In the last 90 days, Agilent Technologies, Inc. insiders filed 0 open-market purchases and 1 sale; 1,135 institutions reported holding it in 13F filings for Q2 2026, worth $34.6B in total; Greenhaven Associates is the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in Agilent Technologies, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,042
- +45 vs. Q2 2025
- Shares held
- 251.0M
- −1.06M (−0.4%) vs. Q2 2025
- Total value
- $32.2B
- +$2.46B (+8.3%) vs. Q2 2025
- New holders
- 114
- 359 more added
- Sold out
- 69
- 373 more reduced
13 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting A on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,135 | $34.6B |
| Q1 2026 | 1,077 | $28.9B |
| Q4 2025 | 1,149 | $34.9B |
| Q3 2025 | 1,042 | $32.2B |
| Q2 2025 | 1,010 | $30.1B |
| Q1 2025 | 1,023 | $29.6B |
| Q4 2024 | 1,079 | $34.0B |
| Q3 2024 | 1,054 | $37.2B |
| Q2 2024 | 1,013 | $33.0B |
| Q1 2024 | 1,015 | $37.9B |
| Q4 2023 | 1,007 | $35.7B |
| Q3 2023 | 920 | $28.3B |
| Q2 2023 | 940 | $30.9B |
| Q1 2023 | 987 | $36.2B |
| Q4 2022 | 966 | $38.7B |
| Q3 2022 | 898 | $31.3B |
| Q2 2022 | 887 | $30.6B |
| Q1 2022 | 933 | $34.7B |
| Q4 2021 | 984 | $42.0B |
| Q3 2021 | 945 | $41.5B |
| Q2 2021 | 887 | $38.9B |
| Q1 2021 | 874 | $33.2B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Agilent Technologies, Inc.; share changes are against Q2 2025.